The US Rapid Diagnostics Market is being shaped by several noteworthy trends that reflect advancements in technology and shifts in healthcare practices. A significant trend is the increasing demand for rapid testing solutions that can provide immediate results, driven by a need for faster clinical decision-making.
The COVID-19 pandemic has significantly accelerated the adoption of rapid diagnostics, especially for infectious diseases like influenza and strep throat, fueling interest from both healthcare providers and consumers. This urgent need for timely diagnoses emphasizes the importance of rapid tests in public health systems, showcased by initiatives from the Centers for Disease Control and Prevention (CDC).
Key market drivers include the growing awareness about early disease detection and the need for home-based diagnostic solutions, which have been further promoted by healthcare policies aiming to improve accessibility and affordability. Regulatory approvals have streamlined the process for new rapid diagnostic tests, encouraging innovation in product development.
Additionally, the push for personalized medicine and point-of-care testing has created opportunities for manufacturers to explore novel methodologies. Emerging opportunities lie in the expansion of rapid diagnostic applications beyond infectious diseases, such as chronic disease management and personalized healthcare.
Manufacturers can also capture opportunities by integrating digital health technologies, allowing for better data management and patient engagement. Trends such as increased partnerships between technology firms and healthcare organizations can enhance the reach of rapid diagnostics, supporting advancements in telehealth and remote monitoring.
Ultimately, these trends signal a transformative period for the US Rapid Diagnostics Market, aligning with healthcare's broader goals of efficiency and effectiveness in patient care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Rapid Diagnostics Market Industry is experiencing significant growth due to the rising demand for point-of-care testing (POCT). This is largely driven by the need for quick diagnostic results, particularly in emergency and urgent care settings. According to the American Hospital Association, over 36 million emergency department visits reported a need for rapid diagnostic testing, pointing to a consistent growth in POCT needs.
Major companies such as Abbott Laboratories and Quidel Corporation are at the forefront of developing innovative POCT solutions, which have greatly enhanced the speed of diagnosis for infectious diseases, chronic conditions, and other medical issues. As more healthcare providers adopt these technologies to improve patient outcomes, the market is expected to thrive.
The trend towards decentralization of healthcare services and increased expenditure on healthcare infrastructure are additional factors propelling the growth of the US Rapid Diagnostics Market.
The increased incidence of infectious diseases in the US is another important driver for the US Rapid Diagnostics Market Industry. The Centers for Disease Control and Prevention (CDC) have reported a rise in cases of various infectious diseases, including sexually transmitted infections and respiratory ailments, with certain diseases like chlamydia showing a notable 19% increase from 2014 to 2018.
This surge has created an urgent need for rapid diagnostic tests to facilitate timely detection and treatment, thereby preventing outbreaks. Companies such as Roche Diagnostics are key players in this domain, actively developing sensitive and rapid testing kits that support healthcare providers in managing infectious disease control efforts.
Technological innovation is profoundly influencing the US Rapid Diagnostics Market Industry. Innovations like microfluidic technology and portable testing devices are significantly enhancing diagnostic precision and usability. The US Food and Drug Administration (FDA) has seen an exponential increase in device approvals, with a reported increase of over 50% in the last five years, setting a conducive environment for rapid diagnostics innovation.
Companies including Becton Dickinson and Company and Cepheid are leading the charge in bringing cutting-edge diagnostic technologies to the forefront. This continuous evolution in technology is reducing turnaround times for results and is likely to entice healthcare practitioners toward adopting rapid diagnostics solutions.
Government initiatives and funding have emerged as critical drivers for the US Rapid Diagnostics Market Industry. The US government has invested heavily in healthcare and diagnostics, especially in response to the COVID-19 pandemic, with the Health Resources and Services Administration (HRSA) allocating significant funds to enhance access to rapid diagnostic testing services across various communities.
Such funding supports the development of robust diagnostic frameworks. As a result, companies like Siemens Healthcare are increasingly involving themselves in collaborative projects funded by the government to bolster rapid testing capabilities across the nation. These initiatives not only improve public health outcomes but also create an environment conducive to market growth and innovation in rapid diagnostics.
The Application segment of the US Rapid Diagnostics Market plays a crucial role in enhancing healthcare outcomes through timely and accurate testing solutions. This segment includes various applications such as Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy and Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, and Toxicology Testing.
Blood Glucose Testing is particularly significant due to the increasing prevalence of diabetes in the US, which necessitates regular monitoring and has created demand for user-friendly and reliable testing devices. Infectious Disease Testing remains a priority, especially in light of global health challenges, driving innovations in point-of-care testing and rapid results that significantly enhance patient management.
Cardiometabolic Testing is gaining traction as more emphasis is placed on heart health and the increased incidence of cardiovascular diseases, promoting preventive care and early intervention strategies. Pregnancy and Fertility Testing solutions are critical for family planning, with advancements in at-home testing contributing to their popularity, allowing individuals to track health status with ease.
Fecal Occult Blood Testing is vital for early detection of colorectal cancer, influencing screening practices and impacting overall public health initiatives aimed at reducing cancer mortality rates. In addition, Coagulation Testing is essential for monitoring patients on anticoagulants, ensuring safety and efficacy in treatment, while Toxicology Testing plays an increasingly important role in substance abuse screening and workplace health assessments.
Overall, these applications represent a dynamic and evolving facet of the US Rapid Diagnostics Market, addressing diverse healthcare needs and contributing to improved patient outcomes through accessible diagnostics.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Rapid Diagnostics Market exhibits significant growth within its Product Type segment, primarily driven by the increasing demand for efficient and timely diagnostic solutions. Over the Counter (OTC) Kits have emerged as a crucial component in this landscape, enabling consumers to perform tests in the comfort of their homes, thus enhancing accessibility and convenience in healthcare.
This trend reflects a growing consumer preference for self-diagnosis and proactive health management. Conversely, Professional Kits, utilized predominantly in clinical settings, remain essential for healthcare professionals who require accurate and rapid test results to inform patient care.
These professional solutions often dominate in terms of reliability and comprehensive testing capabilities, catering to a wide spectrum of applications, including infectious diseases and chronic conditions. As a result, the US Rapid Diagnostics Market segmentation highlights diverse opportunities and growth drivers, including technological advancements in testing methodologies, increased public health awareness, and a focus on preventive care.
Moreover, the ongoing challenges posed by emerging health threats underscore the necessity for rapid diagnostic solutions in both home and professional environments, thereby strengthening the market's trajectory.
The US Rapid Diagnostics Market is characterized by a dynamic competitive landscape, driven by a growing demand for quick and reliable diagnostic tests across various healthcare settings. The market has seen significant advancements in technology, with many players developing innovative solutions to improve speed, accuracy, and efficiency in diagnostics.
As healthcare systems increasingly prioritize rapid results to enhance patient outcomes, the competition among manufacturers intensifies. Industry leaders are engaged in continuous research and development initiatives, aiming to expand their product portfolios and capitalize on emerging trends such as point-of-care testing and at-home diagnostics.
The increasing prevalence of infectious diseases and the recent global health crises have further catalyzed the demand for rapid diagnostic solutions, prompting companies to enhance their capabilities and market reach.
Danaher Corporation has established a strong presence in the US Rapid Diagnostics Market, attributed to its diversified portfolio of advanced diagnostics technologies and platforms that cater to various applications. The company's focus on innovation has enabled it to maintain a competitive edge, as it consistently invests in research and development to enhance its offerings.
Through strategic collaborations and partnerships, Danaher has expanded its market footprint, allowing it to deliver integrated solutions that meet the evolving needs of healthcare providers. Its commitment to quality and efficiency in product development, along with a strong brand reputation, has positioned Danaher favorably within the competitive landscape.
The company's strengths lie in its exceptional technical expertise and ability to adapt to changing market dynamics, ensuring sustained growth and relevance in the rapidly evolving diagnostics sector.
Quidel Corporation displays a formidable presence in the US Rapid Diagnostics Market, particularly known for its advancements in point-of-care rapid testing solutions. The company’s portfolio features a range of key products, including rapid immunoassays and molecular diagnostics tailored to infectious disease testing.
Quidel's extensive market presence is reinforced by its focus on developing innovative tests that provide quick and accurate results, contributing to timely patient care. The firm has successfully capitalized on opportunities through strategic mergers and acquisitions, enhancing its product offerings and expanding its operational capabilities.
Quidel’s strengths include its commitment to high-quality testing solutions, strong distribution networks, and the ability to respond swiftly to public health needs, which has proven particularly vital in addressing outbreaks and urgent health concerns within the US market. Its dedication to research and continuous product innovation positions Quidel as a key player in the competitive landscape of rapid diagnostics.
In recent months, the US Rapid Diagnostics Market has experienced notable advancements and developments. Danaher Corporation has expanded its portfolio by enhancing diagnostic capabilities through strategic partnerships and innovative product launches. Quidel Corporation has introduced new rapid test kits for infectious diseases, reflecting an increasing demand for quick testing solutions post-pandemic.
Hologic continues to innovate in women's health diagnostics, while bioMerieux has strengthened its position with new offerings in infectious disease testing. Roche Diagnostics and Abbott Laboratories have also contributed to market growth with novel diagnostic tools. In terms of mergers and acquisitions, BD (Becton, Dickinson and Company) announced its acquisition of a diagnostics company in July 2023, further solidifying its role in the market.
Recent financial reports indicate substantial growth in market valuation among leading companies, positively impacting overall industry dynamics. Over the past two to three years, the market has seen significant technological progress and an increasing shift towards decentralized testing solutions, with companies like Cepheid and Thermo Fisher Scientific leading the trend.
This evolving landscape is shaping the future of rapid diagnostics, meeting the urgent needs of healthcare providers and patients across the United States.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 4.62(USD Billion) |
| MARKET SIZE 2024 | 5.2(USD Billion) |
| MARKET SIZE 2035 | 12.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Danaher Corporation, Quidel Corporation, Hologic, bioMerieux, Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson and Company), PerkinElmer, Thermo Fisher Scientific, Cepheid, TestAmericas, Siemens Healthineers, Arbor Vita Corporation, OraSure Technologies |
| SEGMENTS COVERED | Application, Product Type |
| KEY MARKET OPPORTUNITIES | Point-of-care testing expansion, Telehealth integration for diagnostics, Increased demand for home testing, Growing chronic disease management, Biodefense and infectious disease focus |
| KEY MARKET DYNAMICS | Growing demand for point-of-care testing, Increasing prevalence of infectious diseases, Advancements in diagnostic technologies, Rising healthcare expenditure, Regulatory approvals and compliance challenges |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Rapid Diagnostics Market was valued at 5.02 billion USD in 2024.
By 2035, the US Rapid Diagnostics Market is anticipated to reach a valuation of 12.5 billion USD.
The expected CAGR for the US Rapid Diagnostics Market from 2025 to 2035 is 8.639%.
In 2024, Blood Glucose Testing is projected to have the highest market value at 1.2 billion USD.
Infectious Disease Testing is expected to grow to 4.5 billion USD by 2035.
Major players include Mylan, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, among others.
Pregnancy Fertility Testing is expected to be valued at 0.7 billion USD in 2024.
Challenges include the need for continuous innovation and navigating regulatory approvals in rapid diagnostics.
Key growth drivers include the increasing prevalence of chronic diseases and a growing demand for timely diagnostic results.
Cardiometabolic Testing is expected to reach a market size of 2.5 billion USD by 2035.
The US Rapid Diagnostics Market is expected to be valued at 5.2 billion USD in 2024.
By 2035, the US Rapid Diagnostics Market is projected to be valued at 12.5 billion USD.
The expected CAGR for the US Rapid Diagnostics Market from 2025 to 2035 is 8.3%.
In 2024, the Blood Glucose Testing segment is expected to hold the largest market share valued at 1.4 billion USD.
The Infectious Disease Testing application is projected to have a market value of 3.9 billion USD by 2035.
The Cardiometabolic Testing segment is estimated to have a market value of 1.2 billion USD in 2024.
The Pregnancy & Fertility Testing application is expected to grow to a market value of 1.9 billion USD by 2035.
Key growth drivers for the US Rapid Diagnostics Market include increasing demand for timely diagnostics and advancements in technology.
The Fecal Occult Blood Testing application is projected to have a market value of 1.4 billion USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
